Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CUDC 305

Known as: CUDC-305, CUDC305 
 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

BenzodioxolesImidazoles

Narrower (1)

Debio 0932

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics
Heat shock protein 90 (HSP90) inhibition is an attractive strategy for cancer treatment. Several HSP90 inhibitors have shown… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
2014
2014
Discovery and Bioevaluation of Novel Pyrazolopyrimidine Analogs as Competitive Hsp90 Inhibitors Through Shape‐Based Similarity Screening
Hsp90 as a promising therapeutic target for the treatment of cancer has received great attention. Many Hsp90 inhibitors such as… Expand
2011
2011
Abstract 3249: Design and synthesis of imidazopyridine derivatives as novel HSP90 inhibitors for the treatment of cancer
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL The molecular chaperone heat shock protein 90 (HSP90… Expand
Highly Cited
2009
Highly Cited
2009
CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy
Purpose: We designed and synthesized CUDC-305, an HSP90 inhibitor of the novel imidazopyridine class. Here, we report its unique… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2009
Highly Cited
2009
Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non–small cell lung cancer
CUDC-305 is a heat shock protein 90 (HSP90) inhibitor of the novel imidazopyridine class. Here, we report its activities in non… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2009
2009
Cancer Therapy : Preclinical CUDC-305 , a Novel Synthetic HSP 90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy
Purpose:We designed and synthesized CUDC-305, an HSP90 inhibitor of the novel imidazopyridine class. Here, we report its unique… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE